Utthara Nayar

1.1k total citations
14 papers, 342 citations indexed

About

Utthara Nayar is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Utthara Nayar has authored 14 papers receiving a total of 342 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Utthara Nayar's work include Advanced Breast Cancer Therapies (7 papers), Cancer Genomics and Diagnostics (4 papers) and HER2/EGFR in Cancer Research (3 papers). Utthara Nayar is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Cancer Genomics and Diagnostics (4 papers) and HER2/EGFR in Cancer Research (3 papers). Utthara Nayar collaborates with scholars based in United States, India and Germany. Utthara Nayar's co-authors include Nikhil Wagle, Seth A. Wander, Eric P. Winer, Ofir Cohen, Samuel S. Freeman, Adrienne G. Waks, Nancy U. Lin, Aviv Regev, Michael S. Cuoco and Orit Rozenblatt–Rosen and has published in prestigious journals such as Journal of Clinical Investigation, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Utthara Nayar

14 papers receiving 338 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Utthara Nayar United States 6 193 151 130 98 39 14 342
Y-H Im South Korea 7 288 1.5× 174 1.2× 73 0.6× 68 0.7× 45 1.2× 22 398
Denise Treue Germany 13 147 0.8× 103 0.7× 198 1.5× 154 1.6× 27 0.7× 18 399
Lingzhu Wen China 10 181 0.9× 96 0.6× 153 1.2× 165 1.7× 21 0.5× 24 341
Ruud van der Noll Netherlands 12 213 1.1× 99 0.7× 318 2.4× 59 0.6× 37 0.9× 20 463
J-Y Pierga France 11 376 1.9× 135 0.9× 113 0.9× 183 1.9× 51 1.3× 53 479
Jorge E. Buendia-Buendia United States 5 238 1.2× 157 1.0× 265 2.0× 186 1.9× 23 0.6× 9 512
Smruthy Sivakumar United States 14 232 1.2× 234 1.5× 251 1.9× 209 2.1× 28 0.7× 43 543
H-T. Arkenau United Kingdom 9 299 1.5× 102 0.7× 152 1.2× 61 0.6× 24 0.6× 29 385
Luuk J. Schipper Netherlands 7 224 1.2× 82 0.5× 74 0.6× 165 1.7× 20 0.5× 13 372
Liam Cornell United States 5 181 0.9× 117 0.8× 210 1.6× 73 0.7× 47 1.2× 7 414

Countries citing papers authored by Utthara Nayar

Since Specialization
Citations

This map shows the geographic impact of Utthara Nayar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Utthara Nayar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Utthara Nayar more than expected).

Fields of papers citing papers by Utthara Nayar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Utthara Nayar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Utthara Nayar. The network helps show where Utthara Nayar may publish in the future.

Co-authorship network of co-authors of Utthara Nayar

This figure shows the co-authorship network connecting the top 25 collaborators of Utthara Nayar. A scholar is included among the top collaborators of Utthara Nayar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Utthara Nayar. Utthara Nayar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Nayar, Utthara, et al.. (2024). The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways. Frontiers in Oncology. 14. 1461190–1461190. 1 indexed citations
2.
Gaillard, Stéphanie, Sachin Kumar Deshmukh, Utthara Nayar, et al.. (2024). Characterization of ESR1 mutations in endometrial and ovarian cancers.. Journal of Clinical Oncology. 42(16_suppl). 5598–5598. 1 indexed citations
3.
Qi, Meifang, Utthara Nayar, Leif S. Ludwig, Nikhil Wagle, & Esther Rheinbay. (2021). cDNA-detector: detection and removal of cDNA contamination in DNA sequencing libraries. BMC Bioinformatics. 22(1). 611–611. 3 indexed citations
4.
Wander, Seth A., Pingping Mao, Maxwell R. Lloyd, et al.. (2021). Abstract PD7-08: Igf1r mediates cdk4/6 inhibitor (cdk4/6i) resistance in tumor samples and in cellular models. Cancer Research. 81(4_Supplement). PD7–8. 2 indexed citations
5.
Mao, Pingping, Ofir Cohen, Kailey J. Kowalski, et al.. (2020). Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clinical Cancer Research. 26(22). 5974–5989. 90 indexed citations
6.
7.
Nayar, Utthara, Ofir Cohen, Michael S. Cuoco, et al.. (2018). Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor–directed therapies. Nature Genetics. 51(2). 207–216. 159 indexed citations
8.
Wander, Seth A., Ofir Cohen, Gabriela N. Johnson, et al.. (2018). Whole exome sequencing (WES) in hormone-receptor positive (HR+) metastatic breast cancer (MBC) to identify mediators of resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i).. Journal of Clinical Oncology. 36(15_suppl). 12016–12016. 11 indexed citations
9.
Nayar, Utthara, Ofir Cohen, Adrienne G. Waks, et al.. (2018). Abstract 4952: Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to ER-directed therapies. Cancer Research. 78(13_Supplement). 4952–4952. 2 indexed citations
10.
Nayar, Utthara, Jonathan Reichel, Gunkut Akar, et al.. (2017). Identification of a nucleoside analog active against adenosine kinase–expressing plasma cell malignancies. Journal of Clinical Investigation. 127(6). 2066–2080. 9 indexed citations
11.
Nayar, Utthara, Pin Lü, Rebecca Goldstein, et al.. (2013). Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood. 122(16). 2837–2847. 54 indexed citations
12.
Nayar, Utthara, Pin Lu, Jelena Vider, et al.. (2012). Abstract 4829: A purine scaffold Hsp90 inhibitor has antitumor activity in KSHV-associated malignancies by suppressing vFLIP. Cancer Research. 72(8_Supplement). 4829–4829. 1 indexed citations
13.
Nayar, Utthara, Pin Lu, Jelena Vider, et al.. (2010). Hsp90 is a viable therapeutic target in the treatment of KSHV-associated primary effusion lymphoma. Infectious Agents and Cancer. 5(S1). 1 indexed citations
14.
Singh, Neeta, et al.. (1994). Poly ADP ribosylation as a possible mechanism of microwave--biointeraction.. PubMed. 38(3). 181–4. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Y-H Im Breakdown of academic impact, for papers by Denise Treue Breakdown of academic impact, for papers by Lingzhu Wen Breakdown of academic impact, for papers by Ruud van der Noll Breakdown of academic impact, for papers by J-Y Pierga Breakdown of academic impact, for papers by Jorge E. Buendia-Buendia Breakdown of academic impact, for papers by Smruthy Sivakumar Breakdown of academic impact, for papers by H-T. Arkenau Breakdown of academic impact, for papers by Luuk J. Schipper Breakdown of academic impact, for papers by Liam Cornell
Rankless by CCL
2026